Home > What We Do > Current Trials

study name and who is ELIGIBLE 


ADNET 

Australia wide

Cutting-edge, cost-free specialist diagnostics

The Australian Dementia Network (ADNeT) Screening and Trials initiative is creating opportunities for Australians living with Dementia to access new therapies under development by attracting major international dementia trials to Australia

The initiative provides clinicians with cutting-edge specialist diagnostic techniques at no cost to the patient, with the aim of facilitating recruitment into intervention trials across Australia.

Eligible patients undergo amyloid PET brain imaging, MRIs and comprehensive and neuropsychological assessments. Results are provided to referring clinicians to assist with diagnosis and patient management.

Who can be involved:

  • Male or female, aged 55 – 85 years inclusive, at the time of informed consent
  • Must be diagnosed with mild-moderate cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Has an identified, reliable, study partner
  • Have no serious medical conditions

What is involved:

  • Involves up to 5 study visits, repeated at 2 – yearly intervals
  • Must be able to tolerate MRI and PET scans
  • Must be willing to undergo blood tests
  • Must be willing to undergo memory assessments 

For further information please contact Mark Rodrigues, Clinical Trial Coordinator at Ph: 08 6457 0266 or Email: m.rodrigues@ecu.edu.au


EVOKE / EVOKE+ (Phase 3)

Semaglutide, sold under the brand names of Ozempic and Rybelsus, is a GLP-1 receptor agonist used for the treatment of type 2 diabetes. Recent clinical data has shown that Semagalutine reduces the risk of dementia lowering neuroinflammation. Thus, this Phase 3 study aims to determine the safety and the impact of oral Semaglutide on the cognitive function in subjects with MCI (mild cognitive impairment) or mild Alzheimer’s disease.

Who can be involved:

  • Male or female, aged 55 – 85 years inclusive, at the time of informed consent
  • Must be diagnosed with mild-moderate cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Has an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months before screening

What is involved:

  • Every three months visits
  • 2 years trial duration
  • Oral tablet once a day
  • Must be able to tolerate MRI and PET scans
  • 50% chance of receiving a placebo

For further information please contact Paula Mather, Clinical Trial Coordinator at Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

* Please note that participants in this study may have a chance of being placed on a placebo medication


JANSSEN Autonomy (Phase 2)

WA only

This study aims to evaluate the effect of JNJ-63733657, which is a monoclonal anti-tau antibody to prevent the collection of tau tangles by clearing them from the brain. The study will investigate whether JNJ-63733657 can slow cognitive decline in participants with early Alzheimer’s disease with evidence of elevated brain tau accessed by a PET scan and assess its safety and tolerability.

Who can be involved:

  • Male or female, aged ≥55 – 80 years inclusive, at the time of informed consent
  • Must be diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Has an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months before screening

What is involved:

  • Monthly visits
  • 5 years trial duration
  • Monthly IV injection
  • Must be able to tolerate MRI and PET scans
  • 33% chance of receiving a placebo

For further information please contact Paula Mather, Clinical Trial Coordinator at Ph: (08) 9389 6433 or Email: aarfctd@alzheimers.com.au

* Please note that participants in this study may have a chance of being placed on a placebo medication


EISAI AHEAD 3-45 BAN2401-G000-303 (Phase 3)

WA only

This is a Phase 3 study to test whether treatment with BAN2401, an anti-amyloid monoclonal antibody, prevents cognitive decline and reduces brain amyloid accumulation. The changes in the amount of amyloid by PET scans and tau in the brain will be monitored to determine the efficacy of the investigational medication.

Who can be involved:

  • Male or female, aged 55 – 80 years inclusive, at the time of informed consent
  • Must have risk factors for Alzheimer’s disease (first-degree relative but no formal diagnosis)
  • Has an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months before screening

What is involved:

  • Fortnightly / monthly visits
  • 5 years trial duration
  • Fortnightly / monthly IV injections (fortnightly or monthly depending on your risk of Alzheimer’s disease)
  • Must be able to tolerate MRI and PET scans
  • 50% chance of receiving a placebo

For further information please contact Paula Mather, Clinical Trial Coordinator at Ph: (08) 9389 6433 or Email: aarfctd@alzheimers.com.au

* Please note that participants in this study may have a chance of being placed on placebo medication.


Probucol in Alzheimer’s Study/PIA Study (Phase 2)

WA only

This study aims to determine whether Probucol is effective for slowing the decline in memory and thinking skills in people with MCI (mild cognitive impairment) or mild Alzheimer’s disease, as well as the impact of Probucol on amyloid protein. Probucol is an anti-hyperlipidemic drug initially developed for the treatment of cardiovascular disease. Recent research has shown that Probucol appears to decrease microscopic blood vessel inflammation and reduce exposure to potentially toxic proteins in the brain. These microscopic blood vessels are important for maintaining brain function, cognition, and memory.

Who can be involved:

  • Male or female, aged 18-85 years, at the time of informed consent
  • Must be diagnosed with mild-moderate cognitive impairment due to probable Alzheimer’s disease or mild Alzheimer’s disease
  • Has an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months before screening

What is involved:

  • Weekly visits for five weeks, then approximately every three months
  • 2 years trial duration
  • Daily medication twice a day (oral tablet)
  • A positive amyloid result on a PET scan

For further information please contact Emily Corti, Clinical Trial Coordinator on Ph: 0468 532 458 or Email: piastudy@curtin.edu.au

* Please note that participants in this study may have a chance of being placed on placebo medication


Testosterone Study (Phase 2)

NSW & WA only

This study aims to evaluate the impact of testosterone alone or in combination with fish oil on amyloid load in the brain, as well as whether it affects performance on tests of memory, cognition and function.

Who can be involved:

  • Males aged between 60 to 80 years
  • Does not have a current medical or neurological condition
  • Not currently taking testosterone or diagnosed with hypogonadism
  • Western Australia and New South Wales residents

What is involved:

  • 18-month duration
  • Most visits 8 weeks apart
  • Testosterone/placebo will be administered intramuscularly every 8 weeks
  • Medical examinations, memory tests and brain scans

For further information please contact

WA Contact: Marie Todd, Study Coordinator on Ph: (08) 6304 3966 or Email: trial@alzheimers.com.au

NSW Contact: Jenny Fisher, Clinical Trial Coordinator on Ph: (02) 9812 3575 or Email: trial@alzheimers.com.au

Read more about the TotAL study here

* Please note that participants in this study may have a chance of being placed on placebo medication


Sleep Study 

WA only

This study aims to examine whether improved sleep (better or longer) contributes to better memory and thinking, and improved markers of brain health (assessed using brain imaging). The study will implement a non-pharmacological intervention to improve sleep in older adults who are ‘poor sleepers.

Who can be involved:

  • Male and females aged 60 years to 80 years
  • Residents from Western Australia

What is involved:

  • Attend a sleep improvement program
  • Have your sleep patterns measured
  • Undergo assessments of memory and thinking
  • Undergo brain imaging scans

For further information about the Sleep Study please contact Jo Shaw, Clinical Trial Coordinator at (08) 6457 0264 or email j.shaw@ecu.edu.au